These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19915386)

  • 1. Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.
    Valenti MT; Giannini S; Donatelli L; Realdi G; Lo Cascio V; Dalle Carbonare L
    J Endocrinol Invest; 2010 Apr; 33(4):244-9. PubMed ID: 19915386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.
    Asbagh LA; Uzunoglu S; Cal C
    Int Braz J Urol; 2008; 34(3):355-63; discussion 364. PubMed ID: 18601766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
    BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
    Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.
    Karabulut B; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Uslu R
    Mol Biol Rep; 2011 Jan; 38(1):249-59. PubMed ID: 20349282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
    Sonnemann J; Bumbul B; Beck JF
    Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
    Nogawa M; Yuasa T; Kimura S; Kuroda J; Segawa H; Sato K; Yokota A; Koizumi M; Maekawa T
    Oncol Res; 2005; 15(1):1-9. PubMed ID: 15839301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1.
    Kijima T; Koga F; Fujii Y; Yoshida S; Tatokoro M; Kihara K
    PLoS One; 2013; 8(5):e64615. PubMed ID: 23741352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
    Bühler H; Hoberg C; Fakhrian K; Adamietz IA
    In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
    Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
    Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
    Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
    Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
    Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M
    Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
    Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
    Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.
    Ottewell PD; Wang N; Meek J; Fowles CA; Croucher PI; Eaton CL; Holen I
    Endocr Relat Cancer; 2014 Oct; 21(5):769-81. PubMed ID: 25052474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.
    Milone MR; Pucci B; Bruzzese F; Carbone C; Piro G; Costantini S; Capone F; Leone A; Di Gennaro E; Caraglia M; Budillon A
    Cell Death Dis; 2013 May; 4(5):e641. PubMed ID: 23703386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.